Technology Transfer

Technology transfer capabilities are essential for implementing global studies with the highest quality, especially in onco-hematology for which the techniques used can be very sensitive and require very specific skills. Benefiting from the experience of its mother company, Cerba European Lab, BARC owns a genuine expertise in transfering technologies and implementing them according to the required standards in terms of reproducibility and reliability worldwide, as well as in developing new methods. An example is the integration at BARC Europe and BARC USA of the MACS® technology of Miltenyi Biotech to isolate CD130+ malignant plasma cells in multiple myeloma, ensuring unmet enrichment rates of specimen.